Hemogenyx signs Cellin Technologies deal to manufacture HG-CT-1 CAR-T therapy in Estonia

• Hemogenyx signed a definitive collaboration agreement with Estonia’s Cellin Technologies to manufacture HG-CT-1 CAR-T for relapsed or refractory AML under Estonia’s hospital exemption.
• Deal positions HG-CT-1 for potential near-term revenue via reimbursed patient treatments, subject to authorization by Estonia’s medicines agency.
• Cellin becomes exclusive manufacturing and operational partner in Estonia for five years, using its GMP facility in Tallinn.
• Technology transfer is expected to take about four months, followed by an estimated 90-day regulatory review.
• Hemogenyx keeps HG-CT-1 intellectual property rights; parties will share net operating margin per patient treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hemogenyx Pharmaceuticals plc published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608110200ACCESSWRNAPR_____1205994) on August 11, 2026, and is solely responsible for the information contained therein.